RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Lynn Francesconi to Animals

This is a "connection" page, showing publications Lynn Francesconi has written about Animals.
Connection Strength

0.382
  1. Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol. 2021 Jan; 92:228-240.
    View in: PubMed
    Score: 0.058
  2. Sanders VA, Iskhakov D, Abdel-Atti D, Devany M, Neary MC, Czerwinski KR, Francesconi LC. Synthesis, characterization and biological studies of rhenium, technetium-99m and rhenium-188 pentapeptides. Nucl Med Biol. 2019 Jan - Feb; 68-69:1-13.
    View in: PubMed
    Score: 0.051
  3. Deri MA, Ponnala S, Kozlowski P, Burton-Pye BP, Cicek HT, Hu C, Lewis JS, Francesconi LC. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. Bioconjug Chem. 2015 Dec 16; 26(12):2579-91.
    View in: PubMed
    Score: 0.041
  4. Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, Francesconi LC. Alternative chelator for 8?Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem. 2014 Jun 12; 57(11):4849-60.
    View in: PubMed
    Score: 0.037
  5. Thompson S, Ballard B, Jiang Z, Revskaya E, Sisay N, Miller WH, Cutler CS, Dadachova E, Francesconi LC. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel. Nucl Med Biol. 2014 Mar; 41(3):276-81.
    View in: PubMed
    Score: 0.036
  6. Ballard B, Jiang Z, Soll CE, Revskaya E, Cutler CS, Dadachova E, Francesconi LC. In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma. Cancer Biother Radiopharm. 2011 Oct; 26(5):547-56.
    View in: PubMed
    Score: 0.031
  7. Cyr JE, Pearson DA, Nelson CA, Lyons BA, Zheng Y, Bartis J, He J, Cantorias MV, Howell RC, Francesconi LC. Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent. J Med Chem. 2007 Sep 06; 50(18):4295-303.
    View in: PubMed
    Score: 0.023
  8. Cantorias MV, Howell RC, Todaro L, Cyr JE, Berndorff D, Rogers RD, Francesconi LC. MO tripeptide diastereomers (M=99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals. Inorg Chem. 2007 Sep 03; 46(18):7326-40.
    View in: PubMed
    Score: 0.023
  9. Phipps MD, Cingoranelli S, Bhupathiraju NVSDK, Younes A, Cao M, Sanders VA, Neary MC, Devany MH, Cutler CS, Lopez GE, Saini S, Parker CC, Fernandez SR, Lewis JS, Lapi SE, Francesconi LC, Deri MA. Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals. Inorg Chem. 2023 Dec 18; 62(50):20567-20581.
    View in: PubMed
    Score: 0.017
  10. MacPherson DS, Fung K, Cook BE, Francesconi LC, Zeglis BM. A brief overview of metal complexes as nuclear imaging agents. Dalton Trans. 2019 Oct 07; 48(39):14547-14565.
    View in: PubMed
    Score: 0.014
  11. Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. a-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2. J Nucl Med. 2018 07; 59(7):1020-1027.
    View in: PubMed
    Score: 0.012
  12. Yazdani A, Bilton H, Vito A, Genady AR, Rathmann SM, Ahmad Z, Janzen N, Czorny S, Zeglis BM, Francesconi LC, Valliant JF. A Bone-Seeking trans-Cyclooctene for Pretargeting and Bioorthogonal Chemistry: A Proof of Concept Study Using 99mTc- and 177Lu-Labeled Tetrazines. J Med Chem. 2016 Oct 27; 59(20):9381-9389.
    View in: PubMed
    Score: 0.011
  13. Francesconi LC, Yang YY, Kung MP, Zhang XX, Billings JJ, Guo YZ, Kung HF. Technetium-99m N,N'-bis(2-mercapto-2-methylpropyl)-2-aminobenzylamine: technetium-99m complexes of a novel bis(aminoethanethiol) ligand. J Med Chem. 1994 Sep 30; 37(20):3282-8.
    View in: PubMed
    Score: 0.010
  14. Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with 8?Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013 Jan; 40(1):3-14.
    View in: PubMed
    Score: 0.008
  15. Efange SM, Tu Z, von Hohenberg K, Francesconi L, Howell RC, Rampersad MV, Todaro LJ, Papke RL, Kung MP. 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization. J Med Chem. 2001 Dec 20; 44(26):4704-15.
    View in: PubMed
    Score: 0.004
  16. Canney DJ, Billings J, Francesconi LC, Guo YZ, Haggerty BS, Rheingold AL, Kung HF. Dicarboxylate diamide dimercaptide (N2S2) technetium-99m complexes: synthesis and biological evaluation as potential renal radiopharmaceuticals. J Med Chem. 1993 Apr 16; 36(8):1032-40.
    View in: PubMed
    Score: 0.002
  17. Ohmomo Y, Francesconi L, Kung MP, Kung HF. New conformationally restricted 99mTc N2S2 complexes as myocardial perfusion imaging agents. J Med Chem. 1992 Jan; 35(1):157-62.
    View in: PubMed
    Score: 0.002
  18. Kung HF, Liu BL, Mankoff D, Kung MP, Billings JJ, Francesconi L, Alavi A. A new myocardial imaging agent: synthesis, characterization, and biodistribution of gallium-68-BAT-TECH. J Nucl Med. 1990 Oct; 31(10):1635-40.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support